Xing Li, Shieh Huey S, Selness Shaun R, Devraj Rajesh V, Walker John K, Devadas Balekudru, Hope Heidi R, Compton Robert P, Schindler John F, Hirsch Jeffrey L, Benson Alan G, Kurumbail Ravi G, Stegeman Roderick A, Williams Jennifer M, Broadus Richard M, Walden Zara, Monahan Joseph B
Structural and Computational Chemistry, St. Louis Laboratories,Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, USA.
Biochemistry. 2009 Jul 14;48(27):6402-11. doi: 10.1021/bi900655f.
PH-797804 is a diarylpyridinone inhibitor of p38alpha mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer (aS), first proposed by molecular modeling and subsequently confirmed by experiments. On the basis of structural comparison with a different biaryl pyrazole template and supported by dozens of high-resolution crystal structures of p38alpha inhibitor complexes, PH-797804 is predicted to possess a high level of specificity across the broad human kinase genome. We used a structural bioinformatics approach to identify two selectivity elements encoded by the TXXXG sequence motif on the p38alpha kinase hinge: (i) Thr106 that serves as the gatekeeper to the buried hydrophobic pocket occupied by 2,4-difluorophenyl of PH-797804 and (ii) the bidentate hydrogen bonds formed by the pyridinone moiety with the kinase hinge requiring an induced 180 degrees rotation of the Met109-Gly110 peptide bond. The peptide flip occurs in p38alpha kinase due to the critical glycine residue marked by its conformational flexibility. Kinome-wide sequence mining revealed rare presentation of the selectivity motif. Corroboratively, PH-797804 exhibited exceptionally high specificity against MAP kinases and the related kinases. No cross-reactivity was observed in large panels of kinase screens (selectivity ratio of >500-fold). In cellular assays, PH-797804 demonstrated superior potency and selectivity consistent with the biochemical measurements. PH-797804 has met safety criteria in human phase I studies and is under clinical development for several inflammatory conditions. Understanding the rationale for selectivity at the molecular level helps elucidate the biological function and design of specific p38alpha kinase inhibitors.
PH-797804是一种p38α丝裂原活化蛋白(MAP)激酶的二芳基吡啶酮抑制剂,它源自一种外消旋混合物,是更具活性的阻转异构体(aS),最初通过分子建模提出,随后经实验证实。基于与不同联芳基吡唑模板的结构比较,并得到p38α抑制剂复合物的数十个高分辨率晶体结构的支持,预计PH-797804在广泛的人类激酶基因组中具有高度特异性。我们使用结构生物信息学方法来识别p38α激酶铰链上由TXXXG序列基序编码的两个选择性元件:(i)Thr106,它作为PH-797804的2,4-二氟苯基占据的埋藏疏水口袋的守门人;(ii)吡啶酮部分与激酶铰链形成的双齿氢键,这需要Met109-Gly110肽键进行180度的诱导旋转。肽翻转发生在p38α激酶中,这是由于关键的甘氨酸残基具有构象灵活性。全激酶组序列挖掘显示该选择性基序的出现频率很低。相应地,PH-797804对MAP激酶和相关激酶表现出极高的特异性。在大量激酶筛选中未观察到交叉反应(选择性比>500倍)。在细胞试验中,PH-797804表现出与生化测量结果一致的卓越效力和选择性。PH-797804已在人类I期研究中达到安全标准,目前正在针对多种炎症性疾病进行临床开发。在分子水平上理解选择性的原理有助于阐明p38α激酶抑制剂的生物学功能和设计。